表紙
市場調查報告書

遲發性運動障礙 - 市場調查,流行病學,市場預測 2028年

Tardive Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 534857
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
遲發性運動障礙 - 市場調查,流行病學,市場預測 2028年 Tardive Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 2019年01月01日內容資訊: 英文 100 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的遲發性運動障礙市場相關調查,疾病概要和現行的治療方法,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數、罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊的總括性彙整。

目錄

第1章 簡介

第2章 遲發性運動障礙市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要:遲發性運動障礙

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家遲發性運動障礙的總患病數、罹患數
  • 主要7個國家遲發性運動障礙的總患病數:各國

第5章 遲發性運動障礙的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 遲發性運動障礙的患病數、罹患數
    • 遲發性運動障礙的病例數:各病型
    • 遲發性運動障礙的病例數:性別
    • 遲發性運動障礙的診斷數
    • 遲發性運動障礙的治療可能的病例數
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 已上市治療藥

  • 醫藥品 A
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • 醫藥品 B

第9章 開發平台治療藥

第10章 重點交叉競爭

第11章 新藥

  • 醫藥品 C
    • 醫藥品概要
    • 臨床試驗詳細內容
    • 安全性和有效性的簡介
    • 優點與缺點
    • 開發平台開發趨勢
    • 產品簡介
  • 醫藥品 D

第12章 市場分析遲發性運動障礙:主要7個國家

  • 市場規模
  • 已上市治療藥的市場佔有率
  • 治療藥的銷售量:各產品

第13章 遲發性運動障礙:各國市場分析

  • 美國
    • 市場規模
    • 已上市治療藥的市場佔有率
    • 治療藥的銷售量:各產品
    • 新藥及其對市場的影響
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 報告方法論

  • 出處

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0224

DelveInsight's "Tardive Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Tardive Dyskinesia epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Tardive Dyskinesia Understanding and Treatment Algorithm

The market report provides the overview of the Tardive Dyskinesia by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Tardive Dyskinesia Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Tardive Dyskinesia in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Tardive Dyskinesia Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Tardive Dyskinesia Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Tardive Dyskinesia market.

Tardive Dyskinesia Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Tardive Dyskinesia Report Insights

  • Patient Population in Tardive Dyskinesia
  • Therapeutic Approaches in Tardive Dyskinesia
  • Tardive Dyskinesia Pipeline Analysis
  • Tardive Dyskinesia Market Size and Trends
  • Tardive Dyskinesia Market Opportunities
  • Impact of upcoming Therapies in Tardive Dyskinesia

Tardive Dyskinesia Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Tardive Dyskinesia Report Assessment

  • Current Treatment Practices in Tardive Dyskinesia
  • Unmet Needs in Tardive Dyskinesia
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Tardive Dyskinesia market
  • Organize sales and marketing efforts by identifying the best opportunities for Tardive Dyskinesia market
  • To understand the future market competition in the Tardive Dyskinesia market.

Table of Contents

1. Report Introduction

2. Tardive Dyskinesia Market Overview at a Glance

  • 2.1. Market Share Distribution of Tardive Dyskinesia in 2016
  • 2.2. Market Share Distribution of Tardive Dyskinesia in 2028

3. Disease Background and Overview: Tardive Dyskinesia

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Tardive Dyskinesia in 7MM
  • 4.3. Total Prevalent Patient Population of Tardive Dyskinesia in 7MM - By Countries

5. Epidemiology of Tardive Dyskinesia by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.1.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.1.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.1.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.1.6. Treatable Cases of the Tardive Dyskinesia
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.4.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.4.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.4.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.4.6. Treatable Cases of the Tardive Dyskinesia
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.5.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.5.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.5.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.5.6. Treatable Cases of the Tardive Dyskinesia
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.6.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.6.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.6.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.6.6. Treatable Cases of the Tardive Dyskinesia
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.7.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.7.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.7.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.7.6. Treatable Cases of the Tardive Dyskinesia
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.8.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.8.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.8.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.8.6. Treatable Cases of the Tardive Dyskinesia
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Tardive Dyskinesia
    • 5.9.3. Sub-Type Specific cases of the Tardive Dyskinesia *
    • 5.9.4. Sex- Specific Cases of the Tardive Dyskinesia *
    • 5.9.5. Diagnosed Cases of the Tardive Dyskinesia
    • 5.9.6. Treatable Cases of the Tardive Dyskinesia

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Tardive Dyskinesia

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Tardive Dyskinesia

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Tardive Dyskinesia : 7MM Market Analysis

  • 12.1. 7MM Market Size of Tardive Dyskinesia
  • 12.2. 7MM Percentage Share of drugs marketed for Tardive Dyskinesia
  • 12.3. 7MM Market Sales of Tardive Dyskinesia by Products

13. Tardive Dyskinesia : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Tardive Dyskinesia in United States
    • 13.1.2. Percentage Share of drugs marketed for Tardive Dyskinesia in United States
    • 13.1.3. Market Sales of Tardive Dyskinesia by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Tardive Dyskinesia in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Tardive Dyskinesia in Germany
      • 13.2.1.3. Market Sales of Tardive Dyskinesia by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Tardive Dyskinesia in France
      • 13.2.2.2. Percentage Share of drugs marketed for Tardive Dyskinesia in France
      • 13.2.2.3. Market Sales of Tardive Dyskinesia by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Tardive Dyskinesia in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Tardive Dyskinesia in Italy
      • 13.2.3.3. Market Sales of Tardive Dyskinesia by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Tardive Dyskinesia in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Tardive Dyskinesia in Spain
      • 13.2.4.3. Market Sales of Tardive Dyskinesia by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Tardive Dyskinesia in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Tardive Dyskinesia in United Kingdom
      • 13.2.5.3. Market Sales of Tardive Dyskinesia by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Tardive Dyskinesia in Japan
    • 13.3.2. Percentage Share of drugs marketed for Tardive Dyskinesia in Japan
    • 13.3.3. Market Sales of Tardive Dyskinesia by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Tardive Dyskinesia in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Tardive Dyskinesia in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Tardive Dyskinesia in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Table 7: Treatable Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Table 12: Treatable Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Tardive Dyskinesia in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Tardive Dyskinesia in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Tardive Dyskinesia in France (2016-2028)
  • Table 16: Diagnosed Cases of the Tardive Dyskinesia in France (2016-2028)
  • Table 17: Treatable Cases of the Tardive Dyskinesia in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Table 22: Treatable Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Table 27: Treatable Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Tardive Dyskinesia in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Table 32: Treatable Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Table 37: Treatable Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 42:7MM- Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 45: United States-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 48: Germany-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 51: France-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 54: Italy-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 57: Spain-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 60:UK-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Table 63: Japan-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Tardive Dyskinesia in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Tardive Dyskinesia in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Tardive Dyskinesia in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Figure 7: Treatable Cases of the Tardive Dyskinesia in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Tardive Dyskinesia in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Tardive Dyskinesia in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Tardive Dyskinesia in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Tardive Dyskinesia in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Tardive Dyskinesia in France (2016-2028)
  • Figure 17: Treatable Cases of the Tardive Dyskinesia in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Tardive Dyskinesia in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Tardive Dyskinesia in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Tardive Dyskinesia in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Figure 32: Treatable Cases of the Tardive Dyskinesia in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Tardive Dyskinesia in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 45: United States-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 51: France-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 60:UK-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Tardive Dyskinesia in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Tardive Dyskinesia by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Tardive Dyskinesia by Therapies in USD MM (2016-2028)